Gene therapy tested in pancreatic cancer studies
Posted on: Tuesday, 15 November 2005, 01:57 CST
LONDON (Reuters) - Gene therapy to block the blood supply to tumors could provide a promising new strategy for treating pancreatic cancer, Chinese scientists said on Tuesday.
In test tube experiments and studies in mice they found the therapy suppressed the formation of new blood vessels, cutting off the nutrient supply needed to grow and spread in the body, although it had little direct effect on the cancerous cells.
In a report in the journal Gut, Dr Yao-Zong Yuan, of Shanghai Second Medical School, said although more research was needed "gene therapy may be a potent strategy to treat many malignant tumors, including pancreatic cancer."
Pancreatic cancer is an extremely difficult cancer to treat because often by the time it is diagnosed it has already spread in the body.
About 216,000 new cases are diagnosed worldwide each year. Surgery is the most effective treatment but the majority of patients die within one year of diagnosis.
The Chinese scientists inserted a gene that produces a protein called vasostatin into a virus, or vector, to deliver it to the cancerous cells.
In the test tube experiments, 72 hours after the cancerous cells were infected with the genetically modified virus the scientists said vasostatin was active. The gene therapy also curbed the growth of pancreatic tumors in the mice.
The causes of pancreatic cancer, which usually occurs in people over 60 years old, are unknown. About 30 percent of cases are attributable to smoking.
Source: REUTERS
Related Articles
- Gene Therapy Technique Fights Cancer By Cutting Off Tumor Blood Supply
- Experimental Therapy Turns On Tumor Suppressor Gene in Cancer Cells
- Recurrent Pancreatic Cancer Therapy Mulled
- Noninvasive Imaging of Cell-Mediated Therapy for Treatment of Cancer
- Chroma to Present Phase I Efficacy Data for Novel Cancer Therapy CHR-2797
- Chroma Progresses Novel Cancer Therapy CHR-2797 Into Phase II Solid Tumour Study; Presents Phase I Data at ASCO
- Pancreatic Cancer Therapy Trial Starts
- ARIAD Grants Second Commercial License to Its Patented ARGENT(TM) Cell-Signaling Regulation Technology for Development of New Cancer Therapies
- VIRxSYS Raises $20 Million in Financing; Funds Will Support Development of Gene Therapies for AIDS and Cancer
- Cancer Therapy; Human papillomavirus L1 renders cells susceptible to NK-mediated destruction
 |
 |
User Comments (0)
RSS Feeds